For investorsA Platform, Not a Product
One living technology, engineered once and pointed at many diseases.
Preclinical
Stage
Pre-seed. No product is approved or on the market.
4
Programmes, one platform
PerioMag · Living Lozenges · Living Hydrogel Coating · GlucoCure
0
Studies in humans
None started. All results to date are lab and animal models.
HKD 17.2M
Indicative plan, 2026 – 2030
Estimated cost of three milestones — not a round size or an amount being raised.
Why these four conditions
Antimicrobial resistance, chronic wounds, device infection and oral disease converge on one unmet need: therapy that arrives in a burst and then fades.
US$700B
Drug-resistant infections
WHO / BMJ Global Health, 2025
US$710B
Oral disease
Journal of Dental Research, 2024
US$149B
Chronic-wound care
Advances in Wound Care, 2025
Roughly US$1.5 trillion in combined annual global economic burden — an approximate sum of the figures above, whose categories partly overlap. Burden is what these diseases cost the world; it is not addressable revenue, and no share of it is claimed or forecast here.
Platform IPEngineered Living Materials spanning microbial engineering and materials science, with patents filed and an accepted Science Advances publication.
PipelineFour programs from one platform:
1. PerioMag
2. Living Lozenges
3. Living Hydrogel Coating
4. GlucoCure
AskCapital to advance lead pre-clinical programs toward first in-human studies, including an HKUMed in-vivo study under ethics review, alongside partners HKU GHFD and Virtus Medical.
Current stage
1. Preclinical
2. Pre-seed
Advancing lead programs (PerioMag & Living Coating) toward first in-human studies.
Next 12–18 months
Pre-clinical validation & CDMO sourcing & the HKUMed in-vivo study (ethics under review)
Use of funds · strategic milestones
Milestone 1Pre-clinical Validation & CDMO SourcingQ3 2026 – Q1 2027HKD 800,000
Living Coating (Animal Study) — in-vivo trials with HKUMed & ethics compliance.Q3–Q4 2026HKD 100,000
PerioMag (CDMO Sourcing) — manufacturer audits & design transfer.Q4 2026 – Q1 2027HKD 700,000
Milestone 2Pilot Clinical Trials & Formulation LockQ2 2027 – Q4 2027HKD 1,400,000
Living Lozenges (Joint Pilot Trial) — CRO small-scale testing & formulation lock.Q2–Q3 2027HKD 200,000
PerioMag (Investigator-Initiated Trials) — pilot clinical validation at a partner dental hospital.Q3–Q4 2027HKD 1,200,000
Milestone 3Industrialization & Regulatory SubmissionQ1 2028 – Q4 2030HKD 15,000,000
PerioMag (Registrational Trials & NMPA) — multicenter trials & Class II regulatory submission.Q1 2028 – Q4 2030HKD 10,000,000
Living Coating (Pilot Line Setup) — SOP engineering runs & coating standardization.Q2 2028 – Q4 2030HKD 5,000,000
Living Lozenges (Mass Commercialization) — consumer-market rollout with a strategic partner.Q3 2028 onwardsPartner-funded
Total estimated budgetHKD 17,200,000
Indicative planning figures across three milestones (Q3 2026 – Q4 2030). Consumer-market rollout of Living Lozenges is planned with a strategic partner. For the non-confidential deck and detailed model, contact the CEO.
How to reach us
This page is for information only. It is not an offer, solicitation or invitation to acquire securities in any jurisdiction, and it is not a prospectus. Timelines, budgets and milestones are forward-looking planning estimates that reflect current intentions and may change. All scientific results described are preclinical — from laboratory cultures and animal models — and no Monexus product is approved, in human studies, or available as a treatment.